Search
Iodide I-123
go.drugbank.com/drugs/DB09420ApprovedInvestigationalAfter incorporation, a gamma camera is used to detect the decay by electron capture to tellurium-123. … Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland.
Ramipril
go.drugbank.com/drugs/DB00178ApprovedInvestigationalRamipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. … Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII).
Mixtures: RAMIPRIL COMP HEU 5/25MG NCategories: Agents Acting on the Renin-Angiotensin SystemFlortaucipir F-18
go.drugbank.com/drugs/DB14914ApprovedInvestigationalIt was approved by the FDA on May 28, 2020, for sale by Avid Radiopharmaceuticals under the name TAUVID™ and is the first FDA-approved molecule for imaging aggregated tau protein in the brain.[L14114] … , as well as to regions containing high levels of melanin, neuromelanin, and iron.
Filgotinib
go.drugbank.com/drugs/DB14845ApprovedInvestigational[A189165] Filgotinib is currently reserved for patients who cannot tolerate DMARDs, or who have been unable to achieve remission in response to one or more DMARDs.[L16616] … [A189165] Non-selective JAK inhibitors like [tofacitinib] target JAK1 and JAK3 subtypes with minimal activity at JAK2. In contrast, the newly approved filgotinib is a highly selective JAK1 inhibitor.
Fezolinetant
go.drugbank.com/drugs/DB15669ApprovedInvestigational[A259591,A259542] By antagonizing NK3 receptors, neuronal signalling can be dampened to reduce VMS. … [A259542] Fezolinetant was approved by the FDA in May 2023 under the brand name Veozah.[L46422] It was subsequently approved by the EMA in December 2023 for the same indication.[L50086]
Hydroxyethyl Starch
go.drugbank.com/drugs/DB09106ApprovedInvestigationalHydroxyethyl starches (HES) are synthetic colloids commonly used for fluid resuscitation to replace intravascular volume. … HES is a general term and can be sub-classified according to average molecular weight, molar substitution, concentration, C2/C6 ratio and Maximum Daily Dose.
rhThrombin
go.drugbank.com/drugs/DB04923ApprovedWithdrawnrhThrombin (recombinant human thrombin) is being developed by ZymoGenetics, Inc. as a general aid to achieving hemostasis during surgery. … The production of recombinant proteins is not dependent on the availability of blood from animals or human donors and can be scaled-up to meet market demand.
Tideglusib
go.drugbank.com/drugs/DB12129ApprovedInvestigationalWithdrawnIt is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3). … [A31601] Tideglusib is being developed by the Spanish pharmaceutic company Zeltia group and its current status is withdrawn for the treatment of Alzheimer's disease as of 2012.
Vigabatrin
go.drugbank.com/drugs/DB01080ApprovedInvestigational[A202124] Its use is now generally reserved for patients who have failed alternative therapies, and its US approval by the FDA in 2009 mandated the creation of a drug registry to monitor patients for visual
Butabarbital
go.drugbank.com/drugs/DB00237ApprovedIllicitWithdrawn[A19735] Its short duration of action gives butabarbital a high abuse potential, comparable to [secobarbital].[A201977,A201980] Butabarbital was granted FDA approval on 5 June 1939.[L13613] … Butabarbital, or Butisol, is a fast onset barbiturate with short duration of action compared to other barbiturates.
International brands: Sarisol No. 2